title: When drug companies select what they want to publish patients are denied relevant therapeutic information.
authors.affiliation: Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
authors.forename: Graziella
authors.initials: G
authors.lastname: Filippini
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Moja
authors.forename: Alessandro
authors.initials: A
authors.lastname: Liberati
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Gensini
authors.forename: Roberto
authors.initials: R
authors.lastname: Gusinu
authors.forename: Andrea A
authors.initials: AA
authors.lastname: Conti
mesh_terms: D002986:Clinical Trials as Topic; D004345:Drug Industry; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011643:Publishing
chemical_list: D016898:Interferon-alpha; D016899:Interferon-beta